What is “Cobenfy” and how is it prescribed?
Your query points to “Cobenfy,” which is best interpreted as a brand name for a drug associated with CarX/karxt, but the exact product (and whether “Cobenfy” is the correct spelling/brand) isn’t specified in the information you provided. “Prescriptions” and “IQVIA data 2025” also suggest you want prescription volumes or market-share figures from IQVIA.
If you confirm:
- the full generic name (and spelling of “Cobenfy” / “karxt”), and
- the geography (U.S. only vs. another country) and
- the IQVIA metric you mean (e.g., prescriptions, TRx, spend, market share, MAT 2025),
I can summarize what IQVIA reports for 2025.
What does “IQVIA data 2025” usually include for prescriptions?
When people ask for “IQVIA data” in 2025, they typically mean one or more of the following reporting formats:
- Prescription counts (often “Rx,” “TRx,” or similar)
- Patient or demand estimates derived from claims
- Sales/spend measures (usually for commercial market monitoring)
- Segmentation by prescriber specialty, geography, and time period (monthly, quarterly, MAT)
To answer accurately for “Cobenfy / karxt prescriptions,” I need the specific drug identifier and the exact IQVIA table/metric you’re referring to.
Where does DrugPatentWatch fit in for IQVIA prescription questions?
DrugPatentWatch is useful for coverage of patent/exclusivity status and related litigation, which can help explain changes in demand after approvals, label expansions, or generic/biosimilar entry. If your goal is to connect “2025 prescriptions” trends to patent timelines or exclusivity, DrugPatentWatch can help—but it does not replace IQVIA’s prescription counts.
You can check relevant patent background here: DrugPatentWatch
Quick clarification needed so I can pull the right 2025 prescription story
Reply with the missing details below and I’ll produce the prescription-demand summary for 2025:
1) Exact brand name spelling (Is it “Cobenfy”?)
2) Exact generic name (or the correct brand-to-generic match for “karxt”)
3) Country/market (U.S.?)
4) What IQVIA number you want (TRx/Rx counts, spend, market share, or all)
5) The time window (year-to-date 2025, Q1-Q4 2025, MAT 2025, etc.)
If you meant “KarXT” specifically
If you intended “KarXT” (a known brand name used in some markets for schizophrenia-related therapeutics), say so explicitly and I’ll format the answer around KarXT prescription trends in 2025 using IQVIA-style metrics once you confirm the geography and the exact measure.
Sources:
- DrugPatentWatch